Anavex Life Sciences Corp (AVXL)

[Anshu2]

EXACTLY my list of issues/concerns with the company’s behavior.

My conclusion is;

1. CM is a coward — doesn’t have the courage to admit trial failures. So makes up endpoint after the results (has certainly happened twice, in all likelihood).

Biggest evidences are — his switches on AUC (!), and plan to go AA after having met all primary endpoints!

2. In addition, CM/company is extremely slow (likely as a result of being CHEAP, and/or taking time to “cook” the endpoints).

3. Small biotechs do indulge in a bit of above. Eg, even SRPT didn’t disclose the WB dys expression numbers in 2015-2016 (not that they really had to, but they seemed very material to many). They came out in FDA’s briefing docs — and were a shocker that the avg expression was only 0.9%. However, they didn’t do any of the lying, or cooking-up of endpoints, etc.